SCHEMBL708244

SCHEMBL708244

CC(C)Cc1ccc(C(=O)NC(C)(C)C)s1

nearest known ligand 0.52

Predicted protein targets (top 20)

geneUniProtsupporting neighboursconfidence
ALDH1A1 P00352 5/20 0.52
HPGD P15428 4/20 0.52
SMN1; SMN2 Q16637 3/20 0.38
RAB9A P51151 2/20 0.38
NPC1 O15118 2/20 0.38
TP53 P04637 1/20 0.38
TSHR P16473 1/20 0.38
HDAC6 Q9UBN7 3/20 0.36
HDAC4 P56524 2/20 0.36
LMNA P02545 1/20 0.36
L3MBTL1 Q9Y468 1/20 0.36
KMT2A Q03164 2/20 0.36
MEN1 O00255 1/20 0.36
SMYD3 Q9H7B4 1/20 0.36
KDM4E B2RXH2 2/20 0.36
NPSR1 Q6W5P4 1/20 0.36
GLA P06280 1/20 0.36
GAA P10253 1/20 0.36
MAPK1 P28482 1/20 0.36
S1PR1 P21453 1/20 0.35

Click a target to see other patent compounds predicted against it — the reverse direction, in place.

Similar compounds — the chemically nearest patent molecules

Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.

Compoundsimilaritytop predictedshared targets
SCHEMBL27336171 0.82 RAB9A (0.54) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL27779290 0.82 ALDH1A1 (0.56) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL19508649 0.79 ALDH1A1 (0.46) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL25564678 0.78 KMT2A (0.45) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL261445 0.76 ALDH1A1 (0.61) ALDH1A1HPGDRAB9ANPC1TSHR
SCHEMBL261525 0.76 ALDH1A1 (0.66) ALDH1A1HPGDTP53LMNAKMT2A
SCHEMBL10130729 0.76 NPC1 (0.54) ALDH1A1HPGDSMN1; SMN2RAB9ANPC1
SCHEMBL19479224 0.76 HDAC3 (0.46) ALDH1A1HPGDSMN1; SMN2TP53TSHR
SCHEMBL8185273 0.76 HPGD (0.56) ALDH1A1HPGDTP53TSHRLMNA
SCHEMBL10130610 0.75 ALDH1A1 (0.59) ALDH1A1HPGDRAB9AL3MBTL1POLB

Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.

Patent provenance — the patents this molecule appears in, and who filed them

Claimed or disclosed in 7 patents. claimed = in the patent's claims; disclosed = body only.

PatentTitleAssigneePublishedPriorityFilingCountryStatus
US-8124638-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2012-02-28 US disclosed
CN-1529697-B Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB 2010-09-22 CN disclosed
US-7652054-B2 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2010-01-26 US disclosed
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists VICORE PHARMA AB 2009-12-31 US disclosed
EP-1395566-B1 TRICYCLIC COMPOUNDS USEFUL AS ANGIOTENSIN II AGONISTS VICORE PHARMA AB (SE) 2007-09-12 EP disclosed
CN-1529697-A Tricyclic compounds useful as angiotensin II agonists ά�ƶ�ҩ�﹫˾ 2004-09-15 CN disclosed
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists VICORE PHARMA AB (SE) 2004-08-26 US disclosed

Patent text — is the patent's own abstract consistent with the prediction?

For each of this compound's patents that has machine-readable text (2 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.

PatentTitleText reads most aboutPredicted target · text-rank
US-20040167176-A1 Tricyclic compounds useful as angiotensin II agonists AGTR1, AGTR2, NPY2R ALDH1A1 3595/4885HPGD 3365/4885SMN1; SMN2 4394/4885
US-20090326026-A1 Tricyclic Compounds Useful as Angiotensin II Agonists AGTR2, AGTR1, NPY4R ALDH1A1 4115/4885HPGD 3447/4885SMN1; SMN2 4272/4885

“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.